<DOC>
	<DOCNO>NCT00781911</DOCNO>
	<brief_summary>Determine 6-month progression free survival ( PFS ) rate associate IMC-A12 combination depot octreotide acetate ( octreotide ) patient metastatic neuroendocrine tumor .</brief_summary>
	<brief_title>A Study IMC-A12 Islet Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>The patient welldifferentiated moderatelydifferentiated , histologically confirm neuroendocrine carcinoma , include carcinoid location islet cell tumors The patient metastatic disease time study entry The patient must tumor measurable accord Response Evaluation Criteria Solid Tumors ( RECIST ) guideline , measurable elevated tumor marker ( eg , 24hour urine 5HIAA , chromogranin A , ACTH , gastrin , tumor specific biochemical marker ) , The patient age ≥ 18 year The patient 's tumor Ki67 expression ≤ 20 % The patient receive depot octreotide therapy time enrol study The patient receive 0 2 systemic anticancer regimens addition depot octreotide , may include chemotherapy , interferon , antiangiogenic therapy , target treatment , combination treatment The patient longer candidate surgery , embolization , radiofrequency ablation therapy The patient experience radiographic , biochemical , and/or scintigraphic disease progression regimen include octreotide The patient complete prior chemotherapy and/or radiotherapy curative intent least 3 week prior administration first dose study therapy . Patients receive palliative radiation therapy bony metastasis prior first dose study medication eligible The patient life expectancy &gt; 3 month The patient Eastern Cooperative Oncology Group performance status ( ECOG PS ) 02 The patient adequate hematologic function define absolute neutrophil count ≥ 1500/μL , hemoglobin ≥ 9 g/dL , platelet count ≥100,000/μL The patient adequate hepatic function define total bilirubin ≤ 1.5 x upper limit normal ( ULN ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3 x ULN ( ≤ 5 x ULN presence know liver metastasis ) The patient either adequate coagulation function define international normalized ratio ( INR ) ≤ 1.5 partial thromboplastin time ( PTT ) 5 second ULN , stable dose anticoagulant The patient adequate renal function define serum creatinine ≤ 1.5 x institutional ULN creatinine clearance ≥ 60 mL/min patient creatinine level ULN The patient fast serum glucose &lt; 160 mg/dL hemoglobin A1c ( HgbA1c ) ≤ 7 . If baseline nonfasting glucose &lt; 160 mg/dL , fast glucose measurement require Because teratogenicity IMCA12 ( cixutumumab ) know , woman childbearing potential ( WOCBP ) must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation The patient ability understand willingness sign write informed consent document The patient uncontrolled brain leptomeningeal metastases The patient recover Grade ≤ 1 adverse event due agent administer 4 week prior study entry ( except alopecia ) The patient receive investigational agent ( ) The patient receive therapeutic radiolabeled somatostatin analogues The patient receive 2 prior regimen systemic therapy metastatic set The patient history treatment agent target IGF receptor The patient history allergic reaction attribute compound chemical biologic composition similar IMCA12 ( cixutumumab ) octreotide The patient poorly control diabetes mellitus . Patients history diabetes mellitus allow participate , provide fast glucose &lt; 160 mg/dL ULN stable dietary therapeutic regimen condition The patient uncontrolled intercurrent illness include , limited , ongoing active infection require parenteral antibiotic , symptomatic congestive heart failure , uncontrolled hypertension , clinically significant cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement The patient pregnant lactate The patient know positive infection human immunodeficiency virus The patient history another primary cancer , exception : ) curatively resect nonmelanomatous skin cancer ; b ) curatively treated cervical carcinoma insitu ; c ) primary solid tumor curatively resect treated know active disease present treatment administer last 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Islet Cell</keyword>
	<keyword>CARCINOMA , ISLET CELL</keyword>
	<keyword>Octreotide</keyword>
	<keyword>depot octreotide acetate</keyword>
	<keyword>Insulin-Like Growth Factor ( IGF ) 1</keyword>
	<keyword>Metastatic , Carcinoid Islet Cell</keyword>
	<keyword>Neuroendocrine Tumors</keyword>
</DOC>